Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Biology Laboratory, |
RCV001281243 | SCV001425067 | likely pathogenic | Nephrotic syndrome, type 9 | 2020-02-01 | criteria provided, single submitter | research | |
Precision Medicine Center, |
RCV001281243 | SCV001593085 | uncertain significance | Nephrotic syndrome, type 9 | criteria provided, single submitter | research | PM1:Located in well-established functional domain PP1:Cosegregation with disease in multiple affected family members PP3:Multiple lines of computational evidence support a deleterious effect on the gene or gene product | |
Sydney Genome Diagnostics, |
RCV001328147 | SCV001449311 | likely pathogenic | Nephrotic syndrome | 2019-05-08 | no assertion criteria provided | clinical testing | This individual is homozygous for the c.748G>C variant in the COQ8B (also known as ADCK4) gene, which results in the amino acid substitution of asparagine to histidine at residue 250, p.(Asp250His). This variant has been reported in the gnomAD browser (http://gnomad.broadinstitute.org) with an allele frequency of 0.075% in the East Asian population (15 out of 19,938 alleles). This variant has been previously reported as homozygous or compound heterozygous with another COQ8B variant in numerous Chinese patients with steroid-resistant nephrotic syndrome (Korkmaz et al 2016 J Am Soc Nephrol 27: 63-68; Wang et al 2017 Pediatr Nephrol 32: 1181-1192; Feng et al 2017 Medicine 96(47): e8880). One patient compound heterozygous for the c.748G>C variant and another COQ8B variant also showed reduced proteinuria upon coenzyme Q10 supplementation (Feng et al 2017). In silico analysis of pathogenicity (through Alamut Visual v2.8.1) using PolyPhen2, SIFT and MutationTaster all predict this variant to be a likely pathogenic variant. This variant is considered to be likely pathogenic according to the ACMG guidelines (Evidence used: PM3_strong, PM2, PP3). |